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Abstract
We respond to criticisms of Mendelian randomization (MR) by Mukamal, Stampfer and Rimm (MSR). MSR consider that 
MR is receiving too much attention and should be renamed. We explain how MR links to Mendel’s laws, the origin of the 
name and our lack of concern regarding nomenclature. We address MSR’s substantive points regarding MR of alcohol and 
cardiovascular disease, an issue on which they dispute the MR findings. We demonstrate that their strictures with respect to 
population stratification, confounding, weak instrument bias, pleiotropy and confounding have been addressed, and summa-
rise how the field has advanced in relation to the issues they raise. We agree with MSR that “the hard problem of conducting 
high-quality, reproducible epidemiology” should be addressed by epidemiologists. However we see more evidence of con-
frontation of this issue within MR, as opposed to conventional observational epidemiology, within which the same methods 
that have demonstrably failed in the past are simply rolled out into new areas, leaving their previous failures unexamined.
Keywords Mendelian randomization · Nutritional epidemiology · Causal inference · Alcohol · Genetic epidemiology
Introduction
Reading what Mukamal, Stampfer and Rimm (henceforth 
MSR) consider to be a “review” [1] of Mendelian randomi-
zation (MR) we felt we had been transported back many 
years. Their essay will read oddly to anyone acquainted with 
MR, as it mainly recapitulates limitations to the approach 
discussed in the first extended exposition [2]. These have 
stimulated the development of a wide range of sensitivity 
analyses, of which MSR appear unaware. Indeed, MSR fail 
to reference a single paper on MR methodology. Rather than 
use up pages of the EJE outlining the basics of MR—of 
which most readers will likely be aware—we refer MSR to a 
few of the many contemporary actual reviews [3–6]. Instead 
we address the substantive issues we can extract from their 
essay. These are (1) MR is receiving more attention than 
the general concept of causality, and has been too eagerly 
adopted; (2) the name “Mendelian randomization” contrib-
utes to its inappropriate popularity and should be changed; 
(3) MSR provide critical commentary on MR of alcohol 
and cardiovascular disease (CVD), an issue in which their 
conventional observational studies have produced widely 
promoted findings; (4) MSR suggest that MR “should be 
treated with the circumspection that should accompany all 
forms of observational epidemiology”; with the latter we 
largely agree.
Mendelian randomization: Is it too popular?
MSR present a figure from Google searches which pur-
ports to show that “worldwide interest in MR has steadily 
increased over the last 10 years, while that of causality more 
generally has not” [1]. We were surprised by this claim, as 
we had investigated the increased interest in causal infer-
ence in epidemiology recently [7] and were not reassured by 
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attempting to replicate MSR’s search strategy. The issue of 
relevance to readers of the EJE will relate to causal inference 
and MR in the epidemiological field. We therefore examined 
citations for the inflexion-point papers for (“causal infer-
ence” and epidemiology) [8] and (“Mendelian randomiza-
tion” and epidemiology) [2]. These are the most highly cited 
papers in their class and ones that heralded a rapid growth in 
publications in their respective areas. As Fig. 1 shows there 
has been interest in both.
What requires no demonstration is that the proportion of 
publications within epidemiology that are concerned with 
causal inference in general, or with MR in particular, have 
increased. We intuit that epidemiological interest in both 
has been driven by the high-profile failures of conventional 
observational epidemiological research of the sort carried 
out by MSR—such as on vitamin E supplement use [9, 10] 
or hormone replacement therapy (HRT) [11] and coronary 
heart disease (CHD), among other topics. Randomised 
controlled trials (RCTs) failed to corroborate their epide-
miological findings. These examples of MSR and their col-
leagues’ work featured prominently in critiques of epide-
miology from different perspectives appearing around the 
millennium [12–15]. RCTs testing hypotheses they advanced 
(e.g. [16, 17]) have continued to produce null results since 
then (e.g. [18, 19]). Concern with the high profile failure 
of these conventional epidemiological studies was a major 
stimulus for formulating ways of strengthening casual infer-
ence within epidemiology, including the introduction of MR 
[2, 20–23]. Indeed, MSR made substantial contributions to 
the development of MR, by repeatedly producing exemplars 
of epidemiological studies which failed to reliably identify 
efficacious targets for interventions to improve population 
health. Illustrating their contribution, Fig. 2 is reproduced 
unchanged from an early paper on MR [24], where it was 
used to encapsulate the failures of conventional epide-
miological studies, making crystal clear the need for new 
methods.
MSR consider the popularity of MR disproportionate. 
Consideration of academic attention to the vitamin E sup-
plementation and HRT papers by MSR [9–11] casts doubt 
on this; they have each been cited more than any empirical 
MR paper. Other highly cited contributions by MSR—
e.g. suggesting that alcohol [25–27], folate supplemen-
tation [28], vitamin C supplements [29] and vitamin D 
[17] protect against CVD, that selenium protects against 
prostate cancer [16], etc., illustrate that high citations are 
Fig. 1  Google Scholar citations 
to the papers that heralded a 
marked upturn in use of the 
terms “causal inference” [8] and 
“Mendelian randomization” [2] 
within epidemiology
Fig. 2  Exemplar of misleading epidemiological research, used to 
illustrate the need to develop alternatives to naïve observational anal-
yses, in an early review of MR (reproduced from [24]). Vitamin E 
supplement use and risk of CHD in two observational studies [9, 10] 
and in a meta-analysis of RCTs [111]. RR: relative risk
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not an indicator of scientific validity. In comparison the 
most highly cited empirical MR paper is one demonstrat-
ing that the inverse association between circulating HDL 
cholesterol (HDL-C) and CHD is unlikely to be causal 
[30], as has now been shown by many RCTs [31]. Whilst 
the first MR study on HDL-C appeared before the first 
large HDL-C raising trial was reported [32], the highly 
cited MR paper was a latter collaborative analysis across 
a large number of studies [30]. In their work, by contrast, 
MSR have simply assumed that HDL-C protects against 
CHD, seeing it as mediating substantial components of the 
apparently beneficial effects of alcohol and HRT on CHD 
[25, 26, 33–35].
We agree that with the advent of two-sample MR, and 
the ease of carrying out these analyses, MR studies can be 
performed with too little thought. Indeed we have published 
a critique of this practice [36], which has some similarities 
with the rapid rise in publication of meta-analyses [37].
Mendelian randomization: What’s in a name?
MSR do not like the name MR, suggesting instead that it be 
referred to as genetic instrumental variables analysis. They 
appear to consider this a novel suggestion, although those 
acquainted with the MR literature will know this proposal 
has been advanced several times before, most coherently in 
2008 [38], to which we responded at the time [39].
MSR dislike use of the term “randomization” in MR 
for two reasons. One is that it assumes that “alleles distrib-
ute freely within open populations; in essence, the latter 
assumes that one’s parents are also randomly assigned” [1]. 
The first extended exposition of MR [2] introduced the con-
cept within the framework of parent-offspring studies, which 
do not require this assumption:
Mendelian randomization is most clearly seen in par-
ent–offspring designs that study the way phenotype 
and alleles co-segregate during transmission from 
parents to offspring. In matings in which at least one 
parent is heterozygous at a polymorphic locus, the 
frequency with which one of the two alleles from a 
heterozygous parent is transmitted to an offspring with 
a particular disease or phenotypic characteristic can 
be evaluated. If there is no association between allelic 
form and the disease or phenotypic characteristic, each 
of the two alleles from the heterozygous parent has a 
50% probability of being transmitted to the offspring 
[2].
The analogy with an RCT was introduced with respect 
to this design:
A shift from this 50/50 ratio indicates an association 
between disease or phenotypic characteristic and the 
alleles at this locus. This study design is closely analo-
gous to that of RCTs as by Mendelian principles there 
should be an equal probability of either allele being 
randomly transmitted to the offspring. [2]
In 2003 it was not possible to utilise this approach:
Such studies may be difficult to carry out however, 
both because of problems in obtaining data from par-
ents and offspring (particularly when parents may be 
dead) and because they generally have lower statisti-
cal power than case-control studies carried out within 
whole populations, rather than within families. [2]
Given the lack of adequately powered studies utilis-
ing a parent-offspring design, population data—and even 
these were sparse—could be used, but the MR was only 
approximate:
Of course populations share much common ancestry 
and the genetic make-up of individuals can be traced 
back through the random segregation of alleles during 
a sequence of matings, but associating genetic markers 
with disease risk or phenotype within such popula-
tions is not as well protected against potential distort-
ing factors as are parent–offspring comparisons. Thus 
the Mendelian randomization in genetic association 
studies is approximate, rather than absolute. [2]
MSR further complain that the word “randomization” in 
MR assumes “meiosis randomly assorts maternal and pater-
nal chromosomes into individual gametocytes” [1]. They 
clearly dispute RA Fisher’s observation that:
Genetics is indeed in a peculiarly favoured condition in 
that Providence has shielded the geneticist from many 
of the difficulties of a reliably controlled comparison. 
The different genotypes possible from the same mat-
ing have been beautifully randomized by the meiotic 
process…..Generally speaking the geneticist, even if 
he foolishly wanted to, could not introduce systematic 
errors into the comparison of genotypes, because for 
most of the relevant time he has not yet recognized 
them. [40]
RA Fisher, seen as the instigator of RCTs, developed 
these by analogy to what is now called Mendelian randomi-
zation [41]:
A connection between our two subjects which seem 
not to be altogether accidental, namely that the “fac-
torial” method of experimentation, now of lively con-
cern so far afield as the psychologists, or the industrial 
chemists, derives its structure and its name, from the 
simultaneous inheritance of Mendelian factors. Geneti-
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cists certainly need not feel that the intellectual debt is 
all on one side [40].
Perhaps MSR have more information on the prevalence of 
transmission ratio distortion—which would be required for 
the non-randomization (beyond, of course, variants in close 
proximity on the same chromosome to those being transmit-
ted, as discussed in [2])—than is available to us. Our review 
of this issue failed to yield such evidence [42]; luckily defini-
tive studies will now be possible, as large genotyped parent-
offspring studies are becoming available.
Regarding naming of the approach, frankly, we don’t care. 
There have been a wealth of proposals from 2004, when 
Tobin et al. suggested “Mendelian deconfounding” [43] 
until 2020, when MSR unconsciously reiterate earlier sug-
gestions, but now with the catchy acronym GIVA [1]. Sadly, 
the acronym GIV (genetic instrumental variables) has been 
adopted by a causal inference method that uses genome-wide 
data [44], so MSR will need to come up with another name 
and acronym. The label Mendelian randomization was only 
adopted because one of us had chanced upon the term—used 
for an ingenious design to utilize the HLA compatibility of 
siblings of children with acute myeloid leukaemia to evalu-
ate the effects of bone marrow transplantation [45]—and 
appropriated it when proposing use of molecular genetic 
data to evaluate the potential causality of homocysteine on 
CVD [46]. Our lack of attachment to the name is public[47], 
with the suggestion that, given a second chance, the formally 
correct “human reverse genetics” might have been a good—
but less catchy—choice. If MSR want to call it GIVA that’s 
fine, although they should perhaps acknowledge that there 
are forms of inference that can come from MR that are not 
encapsulated by conventional understanding of instrumental 
variables analysis [2, 39, 48].
A twice‑told tale: Does alcohol reduce 
cardiovascular risk?
MSR frame their discussion of potential biases in MR analy-
ses in relation to epidemiological evidence on alcohol and 
CVD. Their work has, over many decades, promoted car-
diovascular benefits of alcohol consumption. For example, 
Rimm and Stampfer (as first and senior author) stated in a 
1991 paper—using essentially the same methods they have 
continued with up to this day—that their findings “support 
the hypothesis that the inverse relation between alcohol and 
risk of CHD is causal” and that 40% of the benefit was medi-
ated by increased HDL-C [25]. Their findings suggested a 
linear decrease in CHD risk with increasing alcohol con-
sumption, with the lowest rate being in the highest cate-
gory, those drinking at least the equivalent of 3 US pints of 
the then prevailing beer a day (Fig. 3). In countless further 
papers the basic story—a protective effect of alcohol medi-
ated though HDL-C (with fibrinogen being brought in as 
an additional mediator [26, 27])—has been reiterated, with 
the extension of the apparent protective effects of alcohol to 
hypertensive men [49] and diabetic women [50]. It is there-
fore not surprising that MSR do not like the MR findings 
Fig. 3  Relative risk of coronary 
heart disease by daily alcohol 
consumption, compared to 
non-drinkers. Data from Rimm 
et al. [25]
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suggesting that alcohol increases blood pressure and the risk 
of total CVD [51–53].
MSR’s critique of MR therefore focuses only on issues 
that they perceive as invalidating MR studies of alcohol 
and CVD. There are many more potential limitations that 
those interested in more in-depth analysis can consider [2, 
4, 5, 54]. Here we’ll comment under MSR’s headings on the 
issues they raise.
Confounding
MR studies can suffer from confounding because ancestry 
can influence both the distribution of genotypes and out-
comes in study populations. Obviously, ancestry cannot bias 
genotype-outcome associations between siblings, which is 
why MR was hypothetically introduced in a within-family 
context [2]. Now there are large sibling-pair datasets that 
allow these studies to be performed [42, 55], and for estab-
lished biomedical relationships they produce the expected 
results.
With the huge sample sizes now available in studies such 
as UK Biobank, even a small influence of residual popula-
tion stratification can confound genotype-phenotype asso-
ciations and bias MR estimates, as we have demonstrated 
[56, 57]. Additionally study sampling can generate collider 
bias [58], as there is automatic conditioning on criteria for 
study inclusion, which will include willingness to participate 
and survival up to participation date. Collider bias gener-
ates associations between variables in a sample that can be 
biased downwards or upwards from the associations within 
the source population. We have demonstrated genetic influ-
ences on participation [59, 60], and have begun outlining 
options for recovering valid estimates in such situations [61].
It should be remembered that conventional observational 
studies are also susceptible to bias by ancestry, it has just 
hardly been considered, beyond adjusting or stratifying for 
self-reported ethnicity. In MR studies genome wide data 
are used in addition to self-reports, which allow finer adjust-
ment. Further, we have not seen the collider bias introduced 
in sample selection—e.g. of health professionals who are 
willing to participate in a study—considered in reports of 
such studies. Ironically we discussed an example of where 
collider bias was likely to have generated a spurious “protec-
tive” effect of alcohol on stroke in an early MR paper [62].
MSR suggest ancestry might have biased findings in a 
meta-analytic MR study of a polymorphism in the alcohol 
metabolizing ADH1B gene [63]. The subpopulation they 
consider is not of large enough proportion of the total sample 
to produce substantial bias.
The influence of parental genotypes on offspring through 
the environment provided—stretching from the intrauterine 
period through postnatal life—has been studied in genetic 
epidemiology [64, 65] and referred to as “dynastic effects” 
in MR contexts [42]. Dynastic effects can be investigated 
though use of parental genotype or parental non-transmit-
ted alleles conditional on offspring genotype [66]. Indeed, 
applying this MR approach suggests that maternal alcohol 
consumption leads to lower offspring educational attainment 
[67], which could explain the weak ADH1B-educational 
attainment association that MSR comment on. Regarding 
genetic variants MSR state that MR “must consider the 
actual origin of their presence in an individual’s genome—
the genome of one’s biological parents” [1]. We agree, 
which is why we introduced MR in the context of parent-
offspring studies [2], have elaborated on this approach now it 
is feasible [42], and are demonstrating that, as consideration 
of biological and social realities would lead one to expect, 
for many disease processes such biases in MR are not seen, 
although for social processes—such as educational attain-
ment—they are evident [55]. We have also utilized MR to 
demonstrate assortative mating by alcohol consumption and 
thus by ADH1B genotype [68], which may account for this 
variant being out of Hardy-Weinberg equilibrium in some 
investigations.
A major form of confounding in naïve observational 
studies is that ill-health leads to a reduction or cessation of 
alcohol consumption, often many years before the serious 
disease events or death that are the study outcomes. Illness 
does not influence genotype, which is why MR can provide 
powerful insights into situations in which reverse causality is 
clearly problematic—such as observations that higher BMI 
apparently protects against lung and other cancers, which is 
not supported by MR [69].
Weak instrument bias
MSR discuss weak instrument bias, but not in a way that 
would be recognisable to those familiar with instrumen-
tal variables analysis. Weak instrument bias is generated 
by statistical weakness of association between the genetic 
instrument and exposure of interest, and in single sample 
MR (instrument-exposure and instrument-outcome asso-
ciation both from the same study) this biases findings to 
the (confounded) observational exposure-outcome associa-
tion; however in two sample MR (instrument-exposure and 
instrument-outcome from non-overlapping samples) it biases 
findings to the null [70]. Conventionally if the instrument-
exposure F statistic is > 10 then there is likely to be little 
to no weak instrument bias [71]. In most MR studies of 
ADH1B and (particularly) ALDH2 the F statistics are so 
far above 10 that this is a non-issue [72].
A problem not part of weak instrument bias, although 
MSR consider it is, is exposure misclassification. Simple 
observational studies are more susceptible to this than MR 
studies; the use of genotypic averages (often based on very 
large samples per genotype) considerably lessens the impact 
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of reporting bias by individuals. If an exposure is measured 
with error, its association with an outcome will generally 
under-estimate the causal effect of the exposure on the out-
come. In contrast, as is well known, instrumental variable 
estimators are unbiased if the exposure is non-differentially 
measured with error [73].
Pleiotropy
Horizontal pleiotropy [54] which, in our example, would 
involve a genetic variant influencing alcohol consumption 
and an outcome by independent pathways, is a major con-
cern for MR [74]. Vertical pleiotropy, in which a genetic 
variant influences multiple traits because it has a primary 
influence on alcohol, which in turn influences downstream 
traits, is what MR depends upon [54]. Model organism stud-
ies suggest the latter is a more common phenomenon than 
the former [75, 76]. There is an extensive arsenal of sensi-
tivity analyses that allow for valid estimation in the pres-
ence of horizontal pleiotropy [42, 74]. In the case of alco-
hol the most credible is utilising a group in which genotype 
does not associate with exposure. In studies in some East 
Asian locations women hardly drink alcohol. The ALDH2 
rs671 null variant is prevalent in these populations, lead-
ing to marked symptoms amongst alcohol drinkers. In men 
polymorphism in rs671  relates very strongly to alcohol 
consumption. In women alcohol consumption is very low 
independent of genotype. In men the variant will convey the 
effects of both alcohol and any horizontally pleiotropic path-
ways; in women, only the pleiotropic effects will be seen. 
In men but not women the variant relates strongly to lower 
blood pressure and lower HDL cholesterol; among women 
these associations are not seen [52, 53]. This provides con-
vincing evidence that alcohol elevates blood pressure and 
HDL-C. Furthermore, since sex is clearly not influenced by 
ALDH2 genotype, stratifying on sex is not stratifying on a 
collider [58]. Region of residence will also not be materi-
ally influenced by ALDH2 genotype, and thus joint strati-
fication by sex and region will create groups in which the 
variant relates to a very widely differing extent to alcohol 
consumption. Horizontally pleiotropic effects of the variant 
will not differ between groups. Thus the manner in which 
the ALDH2-alcohol association across groups scales up to 
the adverse CVD consequences of alcohol consumption pro-
vides powerful evidence on the dose-response causal effects 
of alcohol [51]. The difference between the naïve observa-
tional association of alcohol with stroke (which shows the 
usual J-shaped curve generated by confounding and reverse 
causation, as seen in most observational studies) and the 
dose-response increase in stroke seen in the MR analyses is 
stark (Fig. 4a). For CHD the contrast is between the mark-
edly J-shaped observational association and a null estimate 
from MR (Fig. 4b).
MSR comment on acetaldehyde as potentially distorting 
MR results on CVD for the variant in ADH1B. The dis-
ease specific toxicity of acetaldehyde can be easily identi-
fied using MR principles. Alcohol consumption among men 
is very low in ALDH2 homozygous null variant carriers 
(HNV), is intermediate in heterozygotes (HET) and is about 
twice the heterozygote level in homozygous functional allele 
carriers (HFA) [52]. Levels of alcohol-produced acetalde-
hyde is lowest in the HNV group, highest in the HET group 
(who drink alcohol but do not clear the acetaldehyde effi-
ciently) and intermediate in the HFA group. For conditions 
influenced by acetaldehyde—oesophageal and head/neck 
cancer—the highest rates of disease are seen in the HET 
group and the lowest in the HNV group [77, 78]. The higher 
disease risk in HET than HNV demonstrate the contribution 
of acetaldehyde to carcinogenesis; the higher risk in HFA 
than HNV demonstrate that alcohol consumption is a major 
driver of disease incidence[77, 78]. If acetaldehyde were 
influencing CVD or its risk factors then the same shape of 
relationship between genotype and the outcomes would be 
seen, which they are not[51, 52]. The level of acetaldehyde 
generated by alcohol in ADH1B variant carriers is very 
considerably smaller than is seen with ALDH2 genotype. 
The notion that the small difference in acetaldehyde with 
ADH1B has “pleiotropic” effects on CVD and its risk factors 
that are not seen with the order of magnitude greater dif-
ference in acetaldehyde with ALDH2 is simply incoherent.
Regarding drinking behaviours (binge drinking and units) 
these are problematic to investigate in conventional observa-
tional studies—given confounding, misreporting and reverse 
causation—unless one believes that, as Rimm’s data suggest 
(Fig. 3), the highest level of drinking is the best strategy for 
cardiovascular health. As we have seen MR can produce esti-
mates of the shape of the relationship between alcohol and 
health outcomes, and Rimm’s apparently linear decrease in 
CHD risk up to the heaviest drinkers could be tested thought 
the application of non-linear MR [79]. MSR suggest that 
MR studies showing “lower risk of cardiovascular disease 
associated with variants linked to lower alcohol consump-
tion may well be proving the harm of binge drinking” [1]. 
However, across the sex and residential area groups there 
will not be a perfect scaling of effects of genotype on mean 
alcohol consumption and the proportion of binge drinkers. 
Indeed across the lower consumption groups the proportion 
of binge drinkers will be so low as to not credibly produce 
the outcomes seen. The linear effect across mean alcohol 
categories for stroke events in Fig. 4a is also seen for mean 
blood pressure, HDL-cholesterol and ɣ-glutamyltransferase 
[51]; these differences could not be produced by the plausi-
ble proportion of binge drinkers in these groups. This illus-
trates the essential nature of epidemiology as a science of 
group-level outcomes [80], with aggregation at the level of 
genotype reducing bias from measurement and reporting 
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error, together with removing the under-estimated effects of 
reverse causality. In principle the issue of the effect of differ-
ent components of drinking behaviour could be investigated 
through using multivariable MR [81], with genetic variants 
robustly related to any of reported binge drinking, total alco-
hol intake and a composite risk-taking behaviour measure all 
being utilised. Whether this will be possible is speculative at 
this time, but it could allow some interrogation of the issue.
MSR’s suggestion that the absence of an ADH1B effect 
on HDL-C is due to weak instrument bias is not plausible, 
as discussed above. It could be due to pleiotropy or the 
variant being in linkage disequilibrium (LD) with another 
variant that influences HDL-C. In MR there are many 
sensitivity analyses that utilise multiple genetic variants 
related to a trait [74]. As we have seen, the more powerful 
ALDH2 variant, which also allows stratification to exclude 
bias due to pleiotropy or LD—clearly demonstrates an 
effect of alcohol on HDL-C [51, 53]. Furthermore, using 
multiple variants in largely European-origin populations 
with a sample of ~ 1M, a clear effect of alcohol on HDL-C 
is seen, which is robust to stringent interrogation with sen-
sitivity analyses [82]. As HDL-C does not influence CVD 
risk [31, 32] any failure of ADH1B to recapitulate the 
effects of alcohol on HDL-C will not distort the estimates 
of alcohol on cardiovascular outcomes. It may, however, 
herald other potential biases, which is why the use of mul-
tiple instruments and a wide range of sensitivity analyses 
not dependent on a single instrument are routinely insti-
gated in contemporary MR studies.
Fig. 4  A Relative risk (RR) of 
stroke according to drinking 
patterns (left hand panel) and 
MR analyses (right hand panel) 
in men. B RR of coronary heart 
disease according to drinking 
patterns (left hand panel) and 
MR analyses (right hand panel) 
in men [51]
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Adaptation
MSR consider MR “owes its popularity due to its ostensi-
ble ability to test exposures of interest in adulthood” [1], 
but MR is being increasingly used to investigate the effects 
of intrauterine exposures (using maternal non-transmitted 
alleles) [66] and has been widely applied to many childhood 
outcomes. MSR go on to suggest that MR cannot address 
issues of exposure changes over life, but consider Rimm’s 
(Fig. 3) demonstration of the linear decrease in CHD with 
increasingly heavy drinking. The zero or very limited drink-
ing categories could contain many “young and adolescent 
binge drinkers” who quit due to adverse consequences of 
alcohol, on which the investigators probably have no reli-
able data, and thus have findings biased by this. If data on 
earlier life drinking were available on a sufficiently large 
sample then MR could be carried out within the different 
reported categories of earlier drinking behaviour, with less 
confounding and bias than in conventional observational 
epidemiology. A detailed consideration of the meaning of 
MR estimates with respect to interventions at different stages 
of life and with different durations is available [4], and MR 
can provide reliable separation of some exposures acting at 
different periods of life, such as childhood and adulthood 
adiposity [83].
How to be circumspect
MSR state that MR “must be treated with all of the circum-
spection that should accompany all forms of observational 
epidemiology” [1]. We agree, and wonder how such circum-
spection applies to the myriad statements by MSR on the 
causal nature of the cardiovascular protection from alcohol, 
e.g. “the evidence indicates that the association between 
moderate alcohol consumption and lower risk of CHD is 
causal and that abstaining from alcohol could be considered 
a risk factor for CHD” [84]. MSR have also repeatedly made 
strong causal claims regarding raised circulating HDL-C 
mediating a substantial proportion of the apparently protec-
tive effects of alcohol, but HDL-C has been robustly demon-
strated to have no protective effects in many large RCTs and 
MR studies [30–32]. Fibrinogen, the second most impor-
tant mediator according to MSR, appears non-causal in MR 
studies [85]—and we suspect given this evidence there will 
never be an RCT targeting fibrinogen. A valid causal claim 
by MSR is that “half of the beneficial effect of moderate 
alcohol intake is due to increased HDL-C concentrations” 
[27]. This is probably true: best estimates suggest elevated 
HDL-C produces zero benefit, and doubling this equals zero. 
We would support an RCT of long-term difference in alcohol 
intake, but following cancellation of the proposed NIAAA 
MACH15 trial [86] for well documented reasons [87–89] it 
is unlikely this will ever happen.
MSR view investigations of folate supplementation 
and CVD as an appropriate use of MR [1]. Their discus-
sion implies that conventional observational, MR and RCT 
results agree, but this is not the case. MSR’s influential early 
papers on the apparent effect of plasma homocysteine and 
folate intake—which reduces homocysteine—on CHD[28, 
90] suggested a dose-response effect of folate in north Amer-
ican populations. They concluded that their “results suggest 
that any widespread increase in folate intake will have a 
favourable impact on CHD rates” [28]. Both MR [91, 92] 
and many RCTs [93] in such populations show this is spu-
rious. MSR now consider folate supplementation reduces 
stroke in low folate intake populations. We are not convinced 
by even this conclusion, but what is clear is that their origi-
nal observational findings regarding CHD were spurious. 
MSR’s conventional observational studies made other strong 
claims—for example, that folate would reduce blood pres-
sure [94]—that we note they do not revisit. Reading the cur-
rent RCT and MR evidence on this issue may explain why.
MSR discuss two applied MR issues: alcohol and folate. 
We think their disappointment regarding MR could be an 
abreaction to their earlier enthusiasm for the incorporation 
of genetic variants in epidemiological studies to strengthen 
causal inference. In a paper concluding that their genetic 
analysis provided support for the notion that alcohol was 
protective against CHD, partially through HDL-C, MRS 
presented a prototype of MR reasoning:
Some have suggested that the inverse association 
between moderate alcohol intake and the risk of myo-
cardial infarction does not represent a true causal rela-
tion, but rather that alcohol is a surrogate for favorable 
socioeconomic or lifestyle factors associated with a 
reduction in risk. It is unlikely that the ADH3 geno-
type is associated with these potentially confounding 
factors, and we observed no such association in our 
data. [95].
They considered that:
Associations observed in nonrandomized epidemio-
logic studies may be attributed to potentially confound-
ing factors. Observed associations between the risk of 
a disease and the presence of functional variants in 
genes that lead to the metabolism or transduction of 
the factor that underlies the disease add substantial 
support to the idea that the exposure to the factor is 
directly related to causation. [95].
In a statement we endorse, they opined that:
Improving our ability to identify specific lifestyle and 
environmental factors as causes of a given disease may 
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prove to be one of the main benefits of the study of 
common variants in metabolic genes and disease. [95].
We approvingly cited this paper in our initial exposition 
of MR [2], although given the small study sample and the 
growing evidence of publication bias in the genetic epide-
miology field [96], said that “more data are required” [2]. 
Subsequently, far larger MR studies with much greater 
statistical power failed to support their preliminary find-
ing. MSR’s attempt to enrol interactions between alcohol 
intake and genetic polymorphism in cholesteryl ester transfer 
protein (CETP) in their formulation of an “alcohol->HDL-
C-> reduced risk of CHD” causal pathway [97] has like-
wise failed to survive the test of time. Ironically, adequately 
powered and designed studies of CETP genetic variation 
have simultaneously established the non-causal nature of 
the circulating HDL-C -> CHD association and have dem-
onstrated that any effect of CETP inhibition on CHD is due 
to its (small) Apo B and LDL cholesterol lowering—rather 
than its substantial HDL-C elevating—effect [98, 99].
A similar story of disillusionment is seen with respect to 
MTHFR (genetic variation in which has been used to sug-
gest involvement of the folate-homocysteine pathway) and 
CHD. Rimm gave a balanced presentation of MR in a review 
of folate and vascular disease [100], concluding that “chief 
among [the limitations of MR] is the need for very large 
sample sizes” [100]. After these very large sample size MR 
studies came along, which together with RCTs [93] ruled out 
a meaningful effect of folate, MSR’s interpretation changed 
to one which—taken to its logical conclusion—acknowl-
edges that their earlier naïve observational studies produced 
spurious findings. In our first formulation of MR we used 
the folate-CHD link as an example of where MR provided 
supportive evidence [2]. We continued to empirically inter-
rogate this issue as more data accrued and concluded that 
publication bias was likely responsible for the suggestion 
that folate was protective in the initial studies [91]. We 
agree with MSR that selective publication is problematic 
for MR [1], as it is for conventional epidemiology. Indeed, 
in the case of MTHFR and CHD researchers have put in the 
effort to expose and correct it. In an international effort that 
interrogated our suggestion of publication bias in MTHFR 
studies [91], Clarke et al. amassed data from unpublished 
studies—clearly not affected by publication bias—and 
showed that MTHFR was unrelated to CHD in all popula-
tions, including those with low prevailing folate levels [92] 
(Fig. 5). They triangulated [20, 101] these MR findings with 
an updated meta-analysis of RCTs of folate supplementation 
Fig. 5  CHD odds ratio (TT 
versus CC MTHFR C677T 
genotype) in each probable 
folate status category, from a 
meta-analyses of 19 unpub-
lished datasets. US United 
States, ANZ Australia, New 
Zealand) [92]
108 G. Davey Smith et al.
1 3
to conclude that together these provided powerful evidence 
against the claims of substantial effects based on MSR’s 
and others’ observational studies [92]. We invite readers of 
the European Journal of Epidemiology to consult this paper 
(and its detailed supplementary material [92]) and contrast 
it with how MSR have accounted for their clearly erroneous 
observational epidemiological findings, in which selective 
publication likely played a role [102, 103].
There is one obvious solution to selective publication, 
which is making research data accessible. MR studies are 
increasingly carried out using data that are available to the 
entire scientific community. This means other investigators 
can attempt to replicate analyses and can investigate why 
misleading findings have been generated and published. 
Such a process led to retraction of an MR paper in which 
analytical errors were made [36, 104]. The data MSR use are 
generally not made available; if others could investigate the 
reasons behind why their methods and publication choices 
[102, 103] have led to misleading results on many issues this 
would greatly advance epidemiological rigor [105].
We propose that epidemiological evidence be considered 
within a triangulation of evidence framework [20, 101]. In 
such, findings from different study types are evaluated—all 
of which may be biased—but selected on the grounds that 
biases across studies are likely to be orthogonal. An example 
of triangulation of MR findings with those from a meta-
analysis of results from RCTs is provided by the above dis-
cussion of  folate and CHD [92], and a general framework 
for triangulation within epidemiology has been proposed 
[20]. RCTs, of course, provide particularly compelling evi-
dence and examples of where naïve observational studies, 
MR and RCTs have all been carried out are informative. 
For example, MSR’s conventional observational studies 
suggested Vitamin D generates cardiovascular benefits [17]; 
emerging in parallel, MR and RCTs have consistently sug-
gested this is spurious [19, 106]. Similarly MSR promoted 
selenium as protective of prostate cancer [16, 107]. RCT 
[18] and MR evidence [108] suggest it is not. As we have 
seen above, MSR have been enthusiastic proponents of the 
CHD-lowering effects of circulating HDL-C; many RCTs 
and MR studies establish this is spurious. Even RCTs can 
be biased, and MR studies certainly can, but the potentially 
orthogonal nature of these biases mean the combined evi-
dence is robust. For example, it could be argued that ~ 5 
years exposure in the RCTs is inadequate to produce benefit, 
but MR studies provide evidence on the effect of life-long 
differences. Whilst MSR’s epidemiological investigations 
have provided a very poor basis for planning trials, we con-
sider that funders, beneficiaries (including the public who 
desire protection from disease without subjection to, at best, 
useless long term intervention) and clinician-scientists will 
include MR in their evaluation of which potential interven-
tions should undergo large-scale randomized evaluation.
MSR conclude that we should “get back to the hard prob-
lem of conducting high-quality, reproducible epidemiology” 
[1]. We agree. A first step in improving epidemiology would 
be to revisit occasions when observational epidemiology 
has produced highly consequential but misleading findings. 
After the appearance of their studies suggesting a few years 
of vitamin E supplement use would substantially reduce 
CHD risk, the use of supplements containing vitamin E 
increased substantially [109], and has taken a long time to 
fall [110], with at best no benefit and potential harm. Surely, 
both circumspection and exploring how to best conduct 
high-quality reproducible epidemiology would involve re-
examining such situations to uncover why the findings were 
so misleading, whilst allowing other investigators access 
to the data for independent investigation? Going forward, 
rather than focus on nomenclature, let us move to a situa-
tion in which triangulation of findings becomes the norm 
in epidemiology, and methods are considered on the basis 
of what they have to add to a reliable evaluation of each 
particular question.
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